[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Geneva Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,75,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637637","investigating-medical-massage-therapy-for-patients-with-sub-acute-lower-back-pain-100637637",false,"NCT07615816","Investigating Medical Massage Therapy for Patients With Sub-Acute Lower Back Pain","Zeel LBP","Inclusion Criteria:\n\n* Active-duty service member\n* 18-64 (inclusive) years of age\n* Medical evidence of subacute low back pain (as indicated by complications lasting 1-3 months)\n* Willingness to comply with treatment and follow-up schedule\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Current dx of any of the following:\n* Presence of significant comorbid pain (e.g., polytrauma)\n* Cancer - active\u002Fongoing treatment for\n* Active Infections, including skin lesions and rashes\n* Flu or other severe cold virus or COVID\n* Severe depression or anxiety\n* Symptomatic Inflammatory\u002FAutoimmune diseases such as Rheumatoid\n* Arthritis and Ankylosing Spondylitis. Acute exacerbation and not in remission\n* High Grade Spondylolisthesis (Grade III and Grade IV)\n* Fibromyalgia\n* Severe Osteoporosis (BMD with T-score of -2.5 or lower, along with the presence of one or more fragility fractures)\n* Neurogenic conditions\n* Spinal Stenosis with active neurogenic claudication\n* Cauda Equina Syndrome - acute\n* Radiating pain below the knee or in the presence of true Neurological signs (numbness\u002Fweakness)\n* Historical dx of any of the following:\n* Spinal Cord injuries with persisting neurogenic sensory or motor loss\n* Lumbar spine back surgery within the past year\n* Received spinal interventions (e.g., surgery, nerve ablations, steroid injections, etc.) within the past 6 months\n* Current use of blood thinners\u002Fanticoagulants\n* Is enrolled or plans to enroll in another clinical trial during this study that would affect the patient's safety or results of this trial\n* \\[Females only\\] Currently pregnant (self-reported) or plans to become pregnant during the study intervention period","ALL","18 Years","64 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to determine if a weekly regimen of Medical Massage Therapy (MMT) with provider-directed care shortens the duration of Medically Restricted Duty Days (MRDD) periods in Active-Duty Service Members with Subacute Lower Back Pain (LBP) compared to provider-directed care alone.\n\nThe main question the study aims to answer is, when used as an adjunct to provider-directed care, a consistent program of MMT provided by a qualified practitioner, will shorten the duration of MRDD periods, reduce pain, and decrease unnecessary healthcare utilization in patients with Subacute LBP compared to provider-directed care alone. Researchers will study this hypothesis through the comparison of Group #1 (provider-directed care alone) and Group #2 (provider-directed care and MMT).\n\nParticipants randomized into the two study groups will be following a 12-week study design (+\u002F- 2 weeks) comprised of their compliance to their provider-directed care, the study intervention (if randomized to Group #2) and study case report forms (CRFs); with a final follow up visit (up to 4 weeks following their final treatment visit).",[27,28,29],"Lower Back Pain","Subacute Lower Back Pain","Medical Massage Therapy",[29,31,28,27],"Active Duty Service Members","RECRUITING","2026-06-03",{"date":35,"type":36},"2026-06-05","ACTUAL",{"date":38,"type":36},"2026-06-01",{"date":40,"type":21},"2027-01-31",{"name":42,"class":43},"The Geneva Foundation","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100618958","efficacy-and-feasibility-trial-of-a-portable-near-infra-red-hematoma-imager-nird-hi-100618958","NCT07338383","Efficacy and Feasibility Trial of a Portable Near Infra-Red Hematoma Imager (NIRD-HI)","An Efficacy and Feasibility Trial of a Portable Near Infra-Red Hematoma Imager for Detection of Intracranial Hemorrhage in the Acute Care Setting","NIRD-HI","Inclusion Criteria:\n\n* 18 to 89 years of age\n* Able to provide written informed consent either by self or legally authorized representative\n* Received head CT imaging on admission\n* Able to complete at least one NIRD-HI scan within 4 hours of head CT\n* Non-operative management planned\n\nExclusion Criteria:\n\n* Presence of penetrating or non-survivable injuries\n* Hemorrhagic shock or large volume transfusion \\[\\>3 units of any blood product within\n\n  1 hour of scan\\]\n* Large open skull wounds, scalp lacerations or surface hematomas prohibiting safe or comfortable sensor placement\n* Presence of heat tattoos or intracranial metal fixtures\n* Cervical injury prolonging C-spine collar\n* Known prisoners or wards of state\n* Any condition or finding that makes the patient unsuitable for image acquisition in the Investigator's opinion",true,"89 Years",{"count":56,"type":21},80,"OBSERVATIONAL","Traumatic Brain Injury (TBI) is a leading cause of death and disability among military personnel, Veterans, and civilians. One of the most dangerous complications of moderate-to-severe TBI is intracranial hemorrhage (ICH). If not identified and treated promptly, ICH can rapidly lead to worsening neurological damage or death. Current diagnostic tools, such as CT scans, are highly effective but impractical for battlefield or resource-limited environments due to their large size and infrastructure dependency.\n\nThe Near-Infrared Detection-Head Imaging (NIRD-HI) system is an innovative, noninvasive device using Near-Infrared Spectroscopy (NIRS) to identify abnormal blood accumulation. Unlike traditional tools, NIRD-HI is compact, lightweight, and portable, making it suitable for remote or austere settings. By dynamically imaging the brain, it generates 3D visualizations that pinpoint the size and location of bleeds, including complex bilateral injuries. This offers a significant improvement over current point-of-injury technologies that lack the resolution to reliably diagnose all forms of ICH.\n\nThis study supports the FY24 Combat Readiness Medical Research Program by advancing battlefield diagnostic and triage capabilities. The research will:\n\n* Evaluate NIRD-HI's accuracy compared to CT imaging.\n* Assess feasibility in real-world acute care settings.\n* Investigate its ability to monitor changes in ICH over time.\n\nThese objectives address the military's need for tools that improve rapid diagnosis and decision-making during emergencies. Implementing this research can revolutionize TBI management. For Service Members, NIRD-HI promises a field-ready solution for early detection, enabling faster intervention and more effective triage. By reducing diagnostic delays, it could save lives and prevent long-term complications. Furthermore, the system supports prolonged field care by providing continuous monitoring of evolving injuries.\n\nThe benefits extend to civilian healthcare, particularly in rural or underserved areas lacking advanced imaging. This accessibility can improve trauma care outcomes for millions, reduce the burden on healthcare systems, and provide equitable distribution of life-saving technology. By addressing gaps in battlefield medicine, this project aims to enhance medical readiness and improve survivability in the most challenging environments.",[60,61,62,63],"Traumatic Brain Injury","Intracranial Hemorrhages","Combat Casualty Care","Point of Care",[60,65,51],"Intracranial Hemorrhage","NOT_YET_RECRUITING","2026-01-05",{"date":69,"type":36},"2026-01-13",{"date":71,"type":21},"2026-01-01",{"date":73,"type":21},"2027-09-29",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":83,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":44},"100547003","passive-detection--sars-cov-2-covid-19-am-breathalyzer-protect-kiosk-for-operational-medicine-100547003","NCT06402318","Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine","A Prospective, Non-interventional, Observational Clinical Validation Study to Analytically Validate the A&M Breathalyzer PROTECT Kiosk Breath Capture System.","COVID-19","Inclusion Criteria:\n\n* Asymptomatic and symptomatic individuals 18 years and older\n* Receiving standard COVID-19, Flu and\u002For RSV screening and testing at BAMC\n* Do not have to be diagnosed with SARS-CoV-19 (COVID-19) but only be screened\n* Ability to understand consent\n\nExclusion Criteria:\n\n* Any individual under age of 18\n* Anyone unable to comply (or be assisted) with study procedures\n* Anyone not able to provide temperature thermal scan, and\u002For perform exhaled breath for approximately 8 seconds",{"count":84,"type":21},100,"The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in diagnostics for operationalization.\n\nTo meet the objective and execute the deliverables for this program of effort, the A\\&M Breathalyzer PROTECT Kiosk will be tested, modified and validated at Brooke Army Medical Center (BAMC). The collaborative efforts between the PI, Dr. Michael Morris at BAMC and Co-Investigator Dr. Tony Yuan at USU- Center for Biotechnology (4D Bio3) will assess the passive detection technology and provide a capability survey of use-case scenarios for different operational settings.\n\nGoals:\n\n1. Optimization and operationalize the A\\&M Breathalyzer PROTECT Kiosk, portable mass spectrometer (MS) Detector for Deployment in Military Operational Medicine Environments. The Breathalyzer will be deployed to BAMC to test its detection capabilities of COVID-19 among symptomatic and asymptomatic COVID-19 carrier vs. those not infected compared to gold standard RT-PCR.\n2. Evaluate the passive sensing, breath capture system, built within the A\\&M Breathalyzer PROTECT Kiosk. The conversion of the active breath capture system, currently requires a straw that the subject breaths into, where then a series of sensors built in the Breathalyzer would automatically sample the exhaled breath within proximity for recent COVID-19 exposure. This task would conclude with a set of sensors and sensor inputs that would be analyzed by the Atomic AI platform built in the device. Field testing at BAMC is planned to determine the level of detection and discrimination for sensor combinations to SARS-CoV2 components and biomarkers detected. This testing would update the Atomic AI algorithm, within the device, to understand the accuracy of positive detection and the resulting sensitivities.",[81,87,88,89,90],"SARS CoV 2 Virus","COVID-19 Pneumonia","COVID-19 Respiratory Infection","COVID-19 Acute Respiratory Distress Syndrome",[92,93,94,95,96,97],"Breathalyzer","COVID-19 detection","Diagnostic Product","Pulmonary","PROTECT Kiosk","Passive Detection","2025-12-03",{"date":100,"type":36},"2025-12-10",{"date":102,"type":36},"2023-12-27",{"date":104,"type":21},"2026-03-30",{"name":42,"class":43},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":44},"100562727","determining-which-regions-of-the-brain-are-active-during-flight-simulation-at-separate-timepoints-during-training-100562727","NCT06606925","Determining Which Regions of the Brain Are Active During Flight Simulation at Separate Timepoints During Training","fMRI Pilots","Inclusion Criteria:\n\n* Active Duty Military Pilots (Instructor Pilot Trainees or Remote Piloted Aircraft Trainees)\n* Age 18-54 years\n* Biological male or female\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Age \\> 60 years\n* Non-active-duty members\n* History of recurrent migraine headaches requiring chronic suppressive medication or prescription drug intervention more frequently than once per year.\n* History of head trauma or traumatic brain injury with any loss of consciousness or with confusion or amnesia of greater than five minutes.\n* History of eye trauma related to a metallic object unless the presence of residual metal has been previously excluded by x-ray.\n* Pregnancy\n* History of significant neurological disease including cerebrovascular disease, demyelinating disease, or infections of the central nervous system (encephalitis, meningitis).\n* History of medical conditions with potential neurological involvement such as obstructive sleep apnea, autoimmune disorders, etc.\n* History of seizures since age six.\n* Claustrophobia or intolerance of the MRI without medication.\n* Any medical contraindication to MRI (ex: foreign bodies, non-MRI compatible pacemaker, metal devices).","54 Years",{"count":115,"type":21},150,[24],"The overall objective is to identify the cognitive circuits associated with military aviator performance by analyzing what anatomic regions of the brain are functionally \"active\" (neuronal circuit) while being performing virtual flight simulations, the Precision Instrument Control Task (PICT). The flight simulation test will be conducted at two separate timepoints while the subject is receiving a Functional Magnetic Resonance Imaging (fMRI) scan to evaluate which anatomic and functional brain function is associated with precise performance. By scanning at multiple time points we aim to quantify changes in functional and anatomic connectivity that occur throughout the course of training.",[119],"Cognitive Performance",[121,122,123,124,119,125,126],"Pilots","Flight Simulator","fMRI","Training","Neuroergonomics","Military","2025-01-13",{"date":129,"type":36},"2025-01-15",{"date":131,"type":36},"2023-09-19",{"date":133,"type":21},"2026-09-18",{"name":42,"class":43},""]